ClinicalTrials.gov
ClinicalTrials.gov Menu

Identifying Factors Underlying the Discontinuation of Triptans

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00890357
Recruitment Status : Completed
First Posted : April 29, 2009
Last Update Posted : March 29, 2013
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Todd J. Schwedt, Mayo Clinic

Brief Summary:
The objective of this study is to identify reasons migraine patients stop using triptan medications for abortive headache treatment. It is hypothesized that inadequate education of the patient at the time of prescribing the triptan is positively associated with triptan discontinuation.

Condition or disease
Migraine Medication Adherence

Study Type : Observational
Actual Enrollment : 292 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Identifying Factors Underlying the Discontinuation of Triptans
Study Start Date : August 2009
Actual Primary Completion Date : June 2012
Actual Study Completion Date : June 2012

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Group/Cohort
Triptan User
Triptan Discontinued




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adult Specialty Headache Clinics
Criteria

Triptan User Inclusion Criteria:

  • Episodic Migraine or Chronic Migraine
  • Have used a triptan medication in the prior 3 months
  • Have used triptan medications for at least 1 year

Triptan Discontinuation Inclusion Criteria:

  • Episodic Migraine or Chronic Migraine
  • Used any triptan medication in the last 2 years
  • Have not used a triptan medication in the last 6 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00890357


Locations
United States, Florida
University of South Florida College of Medicine
Tampa, Florida, United States, 33612
United States, Missouri
Washington University School of Medicine
St. Louis, Missouri, United States, 63110
United States, Ohio
Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195
Sponsors and Collaborators
Mayo Clinic
Merck Sharp & Dohme Corp.
Investigators
Principal Investigator: Todd Schwedt, MD Mayo Clinic

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Todd J. Schwedt, PI, Mayo Clinic
ClinicalTrials.gov Identifier: NCT00890357     History of Changes
Other Study ID Numbers: 09-0111
First Posted: April 29, 2009    Key Record Dates
Last Update Posted: March 29, 2013
Last Verified: March 2013

Additional relevant MeSH terms:
Sumatriptan
Vasoconstrictor Agents
Serotonin 5-HT1 Receptor Agonists
Serotonin Receptor Agonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs